Literature DB >> 16564782

Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.

Bouke P C Hazenberg1, Martin H van Rijswijk, D Albertus Piers, Marjolijn N Lub-de Hooge, Edo Vellenga, Elizabeth B Haagsma, Philip N Hawkins, Pieter L Jager.   

Abstract

PURPOSE: To assess the diagnostic accuracy and additional information provided by 123I-labeled serum amyloid P component (SAP) scintigraphy in patients with systemic and localized amyloidosis. SUBJECTS AND METHODS: 123I-labeled human SAP was injected intravenously into 20 controls and 189 consecutive patients with histologically proven amyloidosis: of AA type in 60 cases, AL type in 80, hereditary ATTR type in 27, and localized amyloidosis in 22 cases. SAP scintigrams were obtained 24 hours after tracer injection and were analyzed for abnormal patterns of uptake. Sensitivity and specificity were determined, and scintigraphic findings were compared with clinical data.
RESULTS: Diagnostic sensitivity of SAP scintigraphy for systemic AA, AL, and ATTR amyloidosis was 90%, 90%, and 48% respectively, and specificity was 93%. The distribution of amyloid was less diverse in AA than in AL type. Myocardial uptake was not visualized in any patient. Splenic amyloid was very frequent (80%) in AA and AL type but rarely detected clinically (14%). Abnormal tracer uptake in the liver and kidneys correlated with disturbed liver function and proteinuria, respectively. Bone marrow uptake was specific for AL (21%) and was more frequent in AL kappa than AL lambda. Localized amyloid deposits were not imaged.
CONCLUSION: SAP scintigraphy is diagnostic of amyloid in most patients with AA and AL type but fewer with hereditary ATTR type, relating to differing distributions and burdens of amyloid in these disorders. It usually reveals more widespread organ involvement than is identified clinically, and certain distributions of amyloid are characteristic of particular fibril types.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16564782     DOI: 10.1016/j.amjmed.2005.08.043

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  41 in total

1.  SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Arie Oosterhof; Toin H van Kuppevelt; Nicole C Smits; Stephen J Kennel
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

2.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

3.  Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software.

Authors:  Tanja Kero; Lars Lindsjö; Jens Sörensen; Mark Lubberink
Journal:  J Nucl Cardiol       Date:  2015-07-15       Impact factor: 5.952

4.  In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Sallie Macy; Emily B Martin; Angela Williams; Keiichi Higuchi; Stephen J Kennel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

5.  Time for new imaging and therapeutic approaches in cardiac amyloidosis.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Walter Noordzij; Johan Bijzet; Bouke P C Hazenberg; Hans L A Nienhuis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-23       Impact factor: 9.236

Review 6.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

7.  Radioimmunodetection of amyloid deposits in patients with AL amyloidosis.

Authors:  Jonathan S Wall; Stephen J Kennel; Alan C Stuckey; Misty J Long; David W Townsend; Gary T Smith; Karen J Wells; Yitong Fu; Michael G Stabin; Deborah T Weiss; Alan Solomon
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

8.  Cardiac amyloidosis: evolving approach to diagnosis and management.

Authors:  Hans K Meier-Ewert; Vaishali Sanchorawala; John L Berk; Frederick L Ruberg
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

9.  A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5.

Authors:  Jonathan S Wall; Tina Richey; Sally Macy; Eric Heidel; Craig Wooliver; Stephen J Kennel
Journal:  Amyloid       Date:  2013-01-17       Impact factor: 7.141

10.  Tc-99m Radiolabeled Peptide p5 + 14 is an Effective Probe for SPECT Imaging of Systemic Amyloidosis.

Authors:  Stephen J Kennel; Alan Stuckey; Helen P McWilliams-Koeppen; Tina Richey; Jonathan S Wall
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.